Lantern Pharma Statistics
Total Valuation
Lantern Pharma has a market cap or net worth of $38.72 million. The enterprise value is $14.95 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Lantern Pharma has 10.78 million shares outstanding. The number of shares has decreased by -0.74% in one year.
| Current Share Class | 10.78M |
| Shares Outstanding | 10.78M |
| Shares Change (YoY) | -0.74% |
| Shares Change (QoQ) | +1.08% |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 12.40% |
| Float | 7.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.83 |
| P/TBV Ratio | 1.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.83, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.83 |
| Quick Ratio | 5.57 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -66.93% and return on invested capital (ROIC) is -44.38%.
| Return on Equity (ROE) | -66.93% |
| Return on Assets (ROA) | -40.12% |
| Return on Invested Capital (ROIC) | -44.38% |
| Return on Capital Employed (ROCE) | -104.59% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$865,884 |
| Employee Count | 24 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.53% in the last 52 weeks. The beta is 1.63, so Lantern Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.63 |
| 52-Week Price Change | -32.53% |
| 50-Day Moving Average | 3.71 |
| 200-Day Moving Average | 3.82 |
| Relative Strength Index (RSI) | 52.52 |
| Average Volume (20 Days) | 44,149 |
Short Selling Information
The latest short interest is 273,109, so 2.53% of the outstanding shares have been sold short.
| Short Interest | 273,109 |
| Short Previous Month | 259,349 |
| Short % of Shares Out | 2.53% |
| Short % of Float | 3.43% |
| Short Ratio (days to cover) | 6.60 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -22.22M |
| Pretax Income | -17.75M |
| Net Income | -20.78M |
| EBITDA | -22.20M |
| EBIT | -22.22M |
| Earnings Per Share (EPS) | -$1.93 |
Full Income StatementBalance Sheet
The company has $24.01 million in cash and $243,657 in debt, giving a net cash position of $23.77 million or $2.20 per share.
| Cash & Cash Equivalents | 24.01M |
| Total Debt | 243,657 |
| Net Cash | 23.77M |
| Net Cash Per Share | $2.20 |
| Equity (Book Value) | 21.19M |
| Book Value Per Share | 1.96 |
| Working Capital | 20.92M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.81 million and capital expenditures -$12,595, giving a free cash flow of -$17.83 million.
| Operating Cash Flow | -17.81M |
| Capital Expenditures | -12,595 |
| Free Cash Flow | -17.83M |
| FCF Per Share | -$1.65 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |